Corrigendum to: "MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma" [Biochim. Biophys. Acta, Gene Regul. Mech. 1861 (2018) 235-245]
1 Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
2 Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy; Health Sciences and Technology - Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Ozzano Emilia, Italy.
3 Children's Cancer Institute Australia for Medical Research, C25 Lowy Cancer Research Centre, UNSW, 2052, Australia.
4 Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy; Health Sciences and Technology - Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Ozzano Emilia, Italy. Electronic address: giovanni.perini@unibo.it.